307 related articles for article (PubMed ID: 11905684)
1. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
3. Design of anticancer prodrugs for reductive activation.
Chen Y; Hu L
Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA
Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
7. Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.
Govaert KM; Nijkamp MW; Emmink BL; Steller EJ; Minchinton AI; Kranenburg O; Borel Rinkes IH
Br J Surg; 2012 Apr; 99(4):567-75. PubMed ID: 22331808
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW; Wouters BG; Wilson WR
Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
[TBL] [Abstract][Full Text] [Related]
10. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Johnson KM; Parsons ZD; Barnes CL; Gates KS
J Org Chem; 2014 Aug; 79(16):7520-31. PubMed ID: 25029663
[TBL] [Abstract][Full Text] [Related]
11. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
[TBL] [Abstract][Full Text] [Related]
13. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
[TBL] [Abstract][Full Text] [Related]
14. Nitroimidazoles as anti-tumor agents.
Liu K; Zhu HL
Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
[TBL] [Abstract][Full Text] [Related]
15. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
16. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
Yin H; Xu Y; Qian X; Li Y; Liu J
Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719
[TBL] [Abstract][Full Text] [Related]
17. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
Denny WA; Wilson WR
J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
[TBL] [Abstract][Full Text] [Related]
18. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
19. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
20. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]